

Press Release

INVESTOR RELATIONS
Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

Contact:

MEDIA RELATIONS
Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752955)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

Progress in Migraine Research, Promius Announces Presentations for the 70th American Academy of Neurology Annual Meeting

PRINCETON, N.J., April 21, 2018 /PRNewswire/ -- Promius Pharma LLC announces its presentations for the 70th American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA, April 21-27, 2018.

Promius will present 3 platform presentations, with one presentation selected for the "Best of" session, and 4 posters including data from the 2017 Migraine in America Symptoms and Treatment (MAST) Study, a longitudinal survey of more than 15,000 migraine patients.

"The latest results from the MAST Study are new milestones in characterizing migraine symptoms," said Richard B. Lipton, MD, Director of Montefiore Headache Center. "A better understanding of the migraine patient journey may help us optimize future treatment approaches."

"Best of" session platform presentation:

- Untangling the Burden of Menstrual Migraine From Headache Frequency: Results from the 2017 MAST Study

Other platform presentations include:

- Predictors of Allodynia in Persons With Migraine: Results from the 2017 MAST Study
- Factors Associated With Medication Overuse In Persons With Migraine: Results from the 2017 MAST Study

The 4 posters are:

- MAST Study: Gender Differences In Treatment Patterns and Unmet Treatment Needs
- Most Bothersome Associated Symptom In Migraine: Results from 2017 MAST Study
- A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura
- Subjects With Episodic Migraine Treated With DFN-02 (Sumatriptan 10 mg + Permeation Enhancer) Report Higher Treatment Satisfaction and Reduced Functional Disability Compared With Placebo

"We are very excited to have such a robust representation of our scientific work at 70th AAN Annual Meeting" said Dr. Sagar Munjal, Vice President, Chief Medical Officer at Promius Pharma. "The MAST Study findings on the most bothersome symptoms is an excellent example of identifying key unmet needs in management of migraine. We are hopeful that DFN-02 will help address these unmet needs."

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release

INVESTOR RELATIONS
Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

Contact:

MEDIA RELATIONS
Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752955)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

About the MAST Study

The MAST Study addresses gaps in knowledge due to changing demographics and treatment options in the US migraine community. MAST was designed to shed light on the current state of migraine symptom characteristics, including the most bothersome migraine symptoms and how pain interferes with daily functioning.

About Promius Pharma LLC

Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.

Contact information:

Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Investor Relations:
Ashish Girotra (USA)
ashishg@drreddys.com
+1 (609) 375-6145

Media Relations:
Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2955

Copyright 2018 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.